

# Ramapo College Immunization Requirements

## **DUE DATE**

Fall Semester Start: June 30th

Spring Semester Start: January 2<sup>nd</sup>

#### IMMUNIZATION POLICY

Failure to complete health requirements will result in a registration hold. Residential students will not be permitted to move in to on campus housing until they are compliant with the Meningitis requirement.

All registered students are required to submit this form if you are taking classes (in person, online, or virtual).

## REQUIRED IMMUNIZATION FORMS

- 1. Take this packet to your health care provider to be completed, signed, and stamped. This form does not have to be used; an official immunization record from your doctor, employer, military, hospital, or previous school can be submitted. Please make sure that all the required information is provided if you are not using this form.
- 2. Once you have obtained your immunization documents, please submit your immunization forms to Health Services via email (<u>immunize@ramapo.edu</u>) or fax at 201-684-7534 or 201-684-7974.
- 3. If you are age 31 or older at the time of admission to Ramapo College of New Jersey, you are exempt from the immunization requirements under NJ State Law.



# **IMMUNIZATION RECORD**

Ramapo Student ID:
R00

		L				
PART	1: COMPLETED BY THE STU sed.	DENT. All information must	be printe	d legibly or form cannot be		
Last Name:		First Name:		Middle Initial:		
DOB:		Start Date:Fall Spri Year:	ng	Cell Number:		
Full-time (12 or more credits) YesNo		Resident Commuter		Residing in the U.S. with a student visaYes No		
PART	2: TO BE COMPLETED AND	SIGNED BY YOUR HEAL	TH CAR	E PROVIDER.		
Α.	TUBERCULOSIS—PLEASE SEE ATTACHMENT 1 TO COMPLY WITH THIS REQUIREMENT. ALL STUDENTS MUST UPLOAD ATTACHMENT 1 ALONG WITH THIS FORM.					
B.	MMR (Measles, Mumps, Rubella)—Two doses of vaccine OR titers showing immunity (COPY OF LAB REPORT REQUIRED).					
	1st dose (given at or after 1st birthday	y):	2 <sup>nd</sup> dose	:		
C.	HEPATITIS B—Completion of three doses of vaccine OR titers showing immunity (COPY OF LAB REPORT REQUIRED). Note: Negative titers will require the student to repeat the series with 3 doses of Hep B.					
	1 <sup>st</sup> dose date: 2 <sup>st</sup>	<sup>nd</sup> dose:	3 <sup>rd</sup> dose	:		
D.	MENINGOCOCCAL ACWY—One dose received AT OR AFTER AGE 16. REQUIRED for all students who are 18 years of age and younger OR any student residing on campus regardless of age. Visit <a href="https://www.ramapo.edu/health/meningitis-information/">https://www.ramapo.edu/health/meningitis-information/</a> for more information on Meningitis.					
	Dose received at or after age 16: Previous dose received at age 10-15:					
E	RECOMMENDED: MENINGOCOCO	CAL B (please circle Trumenb	a or Bexs	sero):		
	1 <sup>st</sup> Dose:	2 <sup>nd</sup> Dose:	3 <sup>rd</sup> [	Dose:		
			•			
F.	HEALTH CARE EXAMINER'S STATEMENT: I HAVE VERIFIED THAT THE INDIVIDUAL I HAVE EXAMINED IS THE NAMED INDIVIDUAL ON THIS FORM AND THAT THE ABOVE TESTS/VACCINATIONS WERE PERFORMED IN THIS OFFICE/LABORATORY, OR I HAVE REVIEWED ANY DOCUMENTATION RELATIVE TO THE STUDENT'S IMMUNIZATION RECORD.					
	License #:	Phone #:				
	Signature of Healthcare Examiner:	'		Date:		
PART 3: TO BE SIGNED BY THE STUDENT—FORM CANNOT BE PROCESSED WITHOUT STUDENT SIGNATURE.						
Student	Signature:	Ramapo Stude	nt ID:			
	ormation provided on this form is corre ize my student standing at Ramapo C					

PLEASE VISIT <a href="https://www.ramapo.edu/health/immunization-info/">https://www.ramapo.edu/health/immunization-info/</a> FOR ANY UPDATES REGARDING RAMAPO COLLEGE'S IMMUNIZATION REQUIREMENTS.



# **TOOL FOR INSTITUTIONAL USE-ATTACHMENT 1**

# Part I: Tuberculosis (TB) Screening Questionnaire (to be completed by incoming students)

Please answer the following o	questions (1 through 6):		
1. Have you ever had close con	tact with persons known or suspec	ted to have active TB disease?	☐ Yes ☐ No
2. Were you born in one of the o	countries or territories listed below	that have a high incidence of active TE	3 disease?
(If yes, please CIRCLE the cour		Ü	Yes No
•			
Afghanistan	Democratic Republic of the	Lithuania	Rwanda
Algeria	Congo	Madagascar	Sao Tome and Principe
Angola	Djibouti	Malawi	Senegal
Argentina	Dominican Republic	Malaysia Maldiyaa	Sierra Leone
Armenia	Ecuador El Solvador	Maldives Mali	Singapore
Azerbaijan Bangladaah	El Salvador	Marshall Islands	Solomon Islands Somalia
Bangladesh Belarus	Equatorial Guinea Eritrea	Mauritania	South Africa
Belize	Eswatini	Mexico	South Sudan
Benin	Ethiopia	Micronesia	Sri Lanka
Bhutan	Fiji	Mongolia	Sudan
Bolivia (Plurinational State of)	Gabon	Morocco	Suriname
Bosnia and Herzegovina	Gambia	Mozambique	Tajikistan
Botswana	Georgia	Myanmar	Thailand
Brazil	Ghana	Namibia	Timor-Leste
Brunei Darussalam	Guatemala	Nauru	Togo
Burkina Faso	Guinea	Nepal	Tunisia
Burundi	Guinea-Bissau	Nicaragua	Turkmenistan
Cabo Verde	Guyana	Niger	Tuvalu
Cambodia	Haiti	Nigeria	Uganda
Cameroon	Honduras	Niue	Ukraine
Central African Republic	India	Pakistan	United Republic of Tanzania
Chad	Indonesia	Palau	Uruguay
China	Iraq	Panama	Uzbekistan
China, Hong Kong SAR	Kazakhstan	Papua New Guinea	Vanuatu
China, Macao SAR	Kenya	Paraguay	Venezuela (Bolivarian
Colombia	Kiribati	Peru	Republic of)
Comoros	Kyrgyzstan	Philippines	Vietnam
Congo	Lao People's Democratic	Qatar	Yemen
Côte d'Ivoire	Republic	Republic of Korea	Zambia
Democratic People's	Lesotho	Republic of Moldova	Zimbabwe
Republic of Korea	Liberia	Romania	
Source: World Health Organization Clohal Heal	Libya	Russian Federation vith average incidence rates of ≥ 20 cases per 100,000 po	anulation
Source: World Health Organization Global Heal	in Observatory, Tuberculosis incidence. Countries w	ntir average incluence rates or 2 20 cases per 100,000 po	opulation.
	ed to one or more of the countries of the countries or terriors. CHECK the countries or terriors.	or territories listed above for a period of tories above)	of Yes No
4. Have you been a resident and term care facilities, and homeles		ate settings (e.g., correctional facilities	s, long- Yes No
5. Have you been a volunteer o TB disease?	r health care worker who served cli	ents who are at increased risk for acti	ve Yes No
		at may have an increased incidence oved, low-income, or abusing drugs or a	
		college requires that you receive TB should be discussed with a health care	
If the answer to all of the above	ve questions is NO, no further tes	ting or further action is required. You	may stop here.
Student's printed name and signature (required):		Date:	
Jigiiatai o (i oquii ou <i>j</i> i		Date.	



### Part II: Clinical Assessment to be completed by Health Care Provider

Clinicians should review and verify the information in Part I. Persons who answered NO to all questions in Part I do not need further testing. Persons who answered YES to any of the questions in Part I are candidates for either the Mantoux tuberculin skin test (TST) or the Interferon Gamma Release Assay (IGRA), unless a previous positive test has been documented.

nas	been documented.
	<ul> <li>History of a positive TB skin test or IGRA blood test? (If yes, document below.)</li> </ul>
	<ul> <li>History of BCG vaccination? (If yes, consider IGRA if possible.)</li> </ul>
1.	TB SYMPTOM CHECK
	Does the student have signs or symptoms of active pulmonary tuberculosis disease?
	If No, proceed to 2 or 3.
	If Yes, check below:
	<ul> <li>Cough (especially if lasting for 3 weeks or longer) with or without sputum production</li> </ul>
	<ul> <li>Coughing up blood (hemoptysis)</li> </ul>
	o Chest pain
	<ul> <li>Loss of appetite</li> </ul>
	<ul> <li>Unexplained weight loss</li> </ul>
	<ul> <li>Night sweats</li> </ul>
	o Fever
	Proceed with additional evaluation to exclude active tuberculosis disease, including tuberculin skin testing,
	chest X-ray, and sputum evaluation as indicated.
2.	TUBERCULIN SKIN TEST (TST): MUST BE PERFORMED IN THE UNITED STATES (IF CURRENTLY LIVING
	OUTSIDE OF THE UNITED STATES, GO TO #3).
	(TST result should be recorded as actual millimeters [mm] of induration, transverse diameter; if no induration,
	write "0." The TST interpretation should be based on mm of induration as well as risk factors.)**

## \*\*INTERPRETATION GUIDELINES

Result: mm of induration

Date Given:\_\_\_/\_\_\_/

### >5 mm is positive:

- Recent close contacts of an individual with infectious TB
- Persons with fibrotic changes on a prior chest X-ray, consistent with past TB disease
- Organ transplant recipients and other immunosuppressed persons (including receiving equivalent of >15mg/d of prednisone for >1 month)

Date Read: \_\_\_\_/\_\_\_\_

\*\*Interpretation: positive\_\_\_\_ negative\_\_\_\_

HIV-infected persons

## > 10 mm is positive:

- Recent arrivals to the U.S. (<5 years) from high-prevalence areas or who resided in one for a significant
  amount of time (The significance of the travel exposure should be discussed with a health care provider
  and evaluated.)</li>
- Injection drug users
- Mycobacteriology laboratory personnel
- Residents, employees, or volunteers in high-risk congregate settings
- Persons with medical conditions that increase the risk of progression to TB disease, including silicosis, diabetes mellitus, chronic renal failure, certain types of cancer (leukemias and lymphomas, cancers of the head, neck, or lung), gastrectomy or jejunoileal bypass and weight loss of at least 10% below ideal body weight.

## >15 mm is positive:

 Persons with no known risk factors for TB who, except for certain testing programs required by law or regulation, would otherwise not be tested.



3. INTERFERON GAMMA RELEASE ASSAY (IGRA): LAB REPORT IS REQUIRED IN ENGLISH.
Date Obtained:/ (circle method) QFT-GIT T-Spot other
Result: negative positive indeterminate borderline (T-Spot only)
4. CHEST X-RAY: REQUIRED IF TST OR IGRA IS POSITIVE (Radiology report is required in English).  Note: a single
Date of chest X-ray:/ Result: normal abnormal
Part III: Management of Positive TST or IGRA  All students with a positive TST or IGRA with no signs of active disease on chest X-ray should receive a recommendation to be treated for latent TB with appropriate medication. However, students in the following groups are at increased risk of progressions from LTBI to TB disease and should be prioritized to begin treatment as soon possible.  • Infected with HIV  • Recently infected with M. tuberculosis (within the past 2 years)  • History of untreated or inadequately treated TB disease, including persons with fibrotic changes on che radiograph consistent with prior TB disease  • Receiving immunosuppressive therapy, such as tumor necrosis factor-alpha (TNF) antagonists, system corticosteroids equivalent to/greater than 15 mg of prednisone per day, or immunosuppressive drug therapy following organ transplantation  • Diagnosed with silicosis, diabetes mellitus, chronic renal failure, leukemia, or cancer of the head, neck, lung  • Have had a gastrectomy or jejunoileal bypass  • Weigh less than 90% of their ideal body weight  • Cigarette smokers and persons who abuse drugs and/or alcohol  Student agrees to receive treatment  Student declines treatment at this time
Health Care Professional
Signature: Date:

